Table 2.

Hematological and clinical parameters of enrolled subjects

Variables	Group I (BC, n=46)	Group II (CTR1, n=28)	Group III (CTR0, n=31)	P-value I vs II	P-value I vs III	P-value II vs III
Degree of bladder wall infiltration
Ta	26
T1	14
T2	6
Tumor grade
Low	18
High	28
Risk of recurrence and progression
Low	17
High	29
Age (years)
Median	65	62	64	0.45	0.68	0.7
Range	45–84	63–81	47–82
SD	9.46	10.2	12.57
Gender
Male	37	24	25	0.33	0.9	0.27
Female	9	4	6
${\text{Leukocytes}}^{(\times {10}^3/\text{mmc})}$
Median	8.15	7.02	7.64	0.36	0.49	0.87
Range	2.21–18.99	5.06–10.74	3.55–12.28
SD	3.47	2.38	2.77
${\text{Neutrophils}}^{(\times {10}^3/\text{mmc})}$
Median	4.85	4.61	4.28	0.68	0.79	0.48
Range	1.04–12.59	2.49–6.3	1.82–9.02
SD	2.15	1.78	2.49
${\text{Lymphocytes}}^{(\times {10}^3/\text{mmc})}$
Median	2.35	1.52	1.68	0.16	0.13	1.00
Range	0.97–15.19	0.6–4.05	0.56–3.33
SD	2.35	1.07	1.12
${\text{Monocytes}}^{(\times {10}^3/\text{mmc})}$
Median	0.545	0.57	0.555	0.86	0.61	0.46
Range	0.25–1.15	0.14–1.33	0.31–1.71
SD	0.221	0.229	0.428

Abbreviations: BC, patients with bladder cancer; CTR1, subjects with bladder inflammation; CTR0, healthy controls; SD, standard deviation; mmc, cubic milliliter.